Boehringer Ingelheim commences local production of first batch of antihypertensive medicines
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines in Algeria
Search
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
COVID-19 and Type 2 diabetes Regional experts shed light latest scientific updates and
COVID-19 and Type 2 diabetes: Regional experts shed light on the latest scientific updates and clinical practices in disease management for patient education